For how we live.
GUARDIAN offered parents of 4,000 babies a genomic screen for 156 treatable conditions on top of the standard heel-prick. Most said yes, and sequencing worked in 99.6% of cases.
A European registry compared 52 transplanted patients with 79 untreated ones over up to 25 years. The benefit was clearest when transplant came before symptoms, and it did not stop progression entirely.
A few drops of blood taken in the first days of life are checked for dozens of rare but treatable disorders. The US panel has grown from 29 conditions to 35, and states adopt each one at very different speeds.
The country's blood-spot programme has run since 2003 and reaches nearly every baby. A pilot adds genomic sequencing — where a study of Qatari genomes suggests the biggest gains lie.
A modelling analysis puts 2.75 million children under five in sub-Saharan Africa living with sickle cell disease. Seven African countries have transplant programmes; approved gene therapies cost millions.